| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916064 | Nuclear Medicine and Biology | 2013 | 6 Pages |
Abstract
Rilotumumab inhibited 18Â F-FDG and 18Â F-FLT accumulation as early as 2 and 4Â days after treatment, respectively, in a mouse tumor model. Further studies to evaluate 18Â F-FDG PET imaging as an early tumor response marker for rilotumumab are warranted. Rilotumumab is currently being tested in patients with MET-positive, advanced gastric and gastroesophageal cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Karen Rex, Xiaoman Z. Lewis, Sundaresan Gobalakrishnan, Charles Glaus, Matthew D. Silva, Robert Radinsky, Teresa L. Burgess, Sanjiv S. Gambhir, Angela Coxon,